Evaluating HCB101 with other treatments for advanced solid tumors

Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Solid Tumors

This study is testing a new treatment called HCB101 combined with other therapies to see if it helps people with advanced solid tumors, especially those with HER2 positive gastric cancer.

Quick facts

• Phase: PHASE1; PHASE2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: FBD Biologics Limited (industry)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 1 site (Jinan, Shandong)
• Trial ID: NCT06771622 on ClinicalTrials.gov

What this trial studies

This is a non-randomized, open-label study designed to assess the safety and efficacy of HCB101 in combination with other agents for patients with advanced solid tumors. The trial includes a dose-escalation phase followed by a dose-expansion phase, allowing researchers to evaluate the pharmacokinetics and preliminary effectiveness of the treatment. Participants will be grouped into cohorts based on specific cancer types and treatment histories, focusing on those with HER2 positive gastric cancer and other advanced solid tumors.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with advanced solid tumors, particularly those with HER2 overexpression in gastric cancer.

Not a fit: Patients with solid tumors that do not express HER2 or those who have already received multiple lines of treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors, potentially improving outcomes.

How similar studies have performed: Other studies have shown promise in using combination therapies for advanced solid tumors, particularly those targeting HER2, indicating potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Subjects are able to understand and willing to provide signed informed consent.
2. Male and female subjects of ≥18 years of age, inclusive, at the time of signing the informed consent.
3. With histologically/cytologically confirmed diagnosis of advanced solid tumors as described below:

   1. Cohort 1: HER2 overexpression positive (IHC 3+ or IHC 2+ and evidence of HER2 amplification by FISH), unresectable locally advanced, recurrent, or metastatic gastric cancer, patients must be previously untreated with systemic treatment; Subject that received neoadjuvant chemotherapy with recurrence \>6 months from completion of therapy are permitted.
   2. Cohort 2: Unresectable locally advanced, recurrent, or metastatic gastric cancer, progression on or after first-line standard treatment; Prior neoadjuvant or adjuvant therapy can be counted as a line of therapy if the subject progressed on or within 6 months of completing neoadjuvant or adjuvant therapy.
   3. Cohort 3: Advanced or metastatic colorectal cancer, RAS (KRAS, NRAS) gene is wild-type, and no BRAF V600E mutation has been identified, progression on or after first-line standard treatment; Prior neoadjuvant or adjuvant therapy can be counted as a line of therapy if the subject progressed on or within 6 months of completing neoadjuvant or adjuvant therapy.
   4. Cohort 4: Recurrent unresectable (local or regional) or stage IV (M1) triple-negative breast cancer TNBC, whose tumors express PD-L1 with a CPS ≥ 10, patients must be previously untreated with systemic treatment; Subject that received neoadjuvant chemotherapy with recurrence \>6 months from completion of therapy are permitted.
4. Have adequate organ function, as indicated by the following laboratory parameters below (had not received a blood transfusion, apheresis infusion, erythropoietin, granulocyte colony-stimulating factor, and other relevant medical support within 14 days before the administration of the first dose of study intervention).

Exclusion Criteria:

1. With a known history of hypersensitivity to any components of the study intervention.
2. Subjects who have other malignancies requiring treatment within 2 years before the first dose of study intervention will be excluded, except for radically treated locally curable basal or squamous cell skin cancer and other malignancies that have been treated with no relapse within 2 years.
3. Subjects who have undergone any investigational or approved systemic cancer therapy (including chemotherapy, immunotherapy, hormonal therapy, and herbal/alternative therapies with anti-cancer indications or targeted therapy) within 14 days or 5 half-lives, whichever is longer, before the first dose of the study intervention.
4. Subjects who have received any treatment targeting the CD47 or SIRPα pathway.
5. An uncontrolled acute infection.
6. Known to have a history of alcoholism or drug abuse.
7. Any other medical (e.g., Child-Pugh class B or C, pulmonary, metabolic, congenital, endocrinal or CNS disease, etc.), psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.

Where this trial is running

Jinan, Shandong

• Cancer Hospital of Shandong First Medical University — Jinan, Shandong, China (RECRUITING)

Study contacts

• Study coordinator: FBD Clinical

Conditions: Solid Cancer